Subject 01-701-1083, an 89-year-old woman with Alzheimer’s dementia, began receiving placebo on 22 July 2013.  The subject was diagnosed with Alzheimer’s dementia in 2011.  This subject had previous history of cardiovascular disease: implanted cardiac pacemaker, first degree atrioventricular block, and a history of myocardial infarction and angina pectoris in 2006.  The subject experienced a fatal myocardial infarction on 2 August 2013.  This event required hospitalization.  The event was considered by the investigator to be possibly related to study medication.  No action was taken for this event and study medication was not discontinued prior to death.  No other adverse events were reported by this subject.

Subject 01-701-1211, a 76-year-old woman with Alzheimer’s dementia, began receiving xanomeline low dose on 15 November 2012.  The subject was diagnosed with Alzheimer’s dementia in 2010.  The subject also had non-insulin dependent diabetes mellitus, which was considered to be mild in severity.  The subject experienced sudden death on 14 January 2013.  This death was considered by the investigator to be unrelated to study medication.  No action was taken for this event and study medication was not discontinued prior to death.  Eight other adverse events were reported for this subject yet none were classified as being serious and none appeared to contribute to the sudden death.

Subject 01-701-1445, a 75-year-old man with Alzheimer’s dementia, began receiving placebo on 11 May 2014.  The subject was diagnosed with Alzheimer’s dementia in 2012.  The subject also suffered from mild forms of non-insulin dependent diabetes mellitus, chronic obstructive pulmonary disease, and benign prostatic hyperplasia.  This subject committed suicide on 31 October 2014.  This death was considered by the investigator to be unrelated to study medication.  No action was taken for this event and study medication was not discontinued prior to death.  No other adverse events were reported by this subject.